Research advance of DNA methylation regulation of miRNAs in breast carcinoma
-
摘要: 微小核糖核酸(miRNA)是一类内源性非编码小RNA, 长约18~25个核苷酸, 其通过与特定靶mRNA结合来抑制mRNA翻译过程, 从而在转录后水平调节靶基因的表达水平, 与恶性肿瘤的发生、发展、侵袭以及转移密切相关。前期大量研究发现, DNA甲基化可能是调控乳腺癌中miRNA表达异常的机制, 包括癌基因miRNA低甲基化激活和抑癌基因miRNA高甲基化失活, 从而导致miRNA调控的下游靶基因表达异常, 参与乳腺癌的发生发展。因此, 本文主要就DNA甲基化调控的miRNA在乳腺癌中的研究进展作一综述。Abstract: Micrornas (miRNAs) are a class of endogenous non-coding small RNA, length of about 18~25 nucleotides, which combined with specific mRNA target for inhibition of mRNA translation process, so as to adjust to change the expression level of target gene at the post-transcriptional level and closely related to the occurrence, development, invasion and metastasis of malignant tumor.Previous researches have shown that DNA methylation may be the regulatory mechanisms of abnormal expression of micrornas in breast cancer, Including micrornas low methylation activation of oncogene and high methylation deactivation of tumor suppressor genes which can lead to abnormal expression of downstream target genes and participate in the development of breast cancer.Therefore, this article were mainly reviewed on regulation of DNA methylation of micrornas in breast cancer.
-
Key words:
- MicroRNA /
- DNA methylation /
- breast carcinoma
-
[1] Johnston SR.New strategies in estrogen receptor-positive breast cancer[J].Clin Cancer Res, 2010, 16:1979-87. doi: 10.1158/1078-0432.CCR-09-1823 [2] Bardhan K, Liu K.Epigenetics and colorectal cancer pathogenesis[J].Cancers (Basel), 2013, 5(2):676-713. doi: 10.3390/cancers5020676 [3] Li BQ, Yu H, Wang Z, et al.MicroRNA mediated network and DNA methylation in colorectal cancer[J].Protein Pept Lett, 2013, 20(3): 352-63. https://www.ncbi.nlm.nih.gov/pubmed/22591477 [4] Puszyk WM, Trinh TL, Chapple SJ, et al.Linking metabolism and epigenetic regulation in development of hepatocellular carcinoma[J].Lab Invest, 2013, 93(9):983-90. doi: 10.1038/labinvest.2013.94 [5] Jung EJ, Kim IS, Lee EY, et al.Comparison of methylation profiling in cancerous and their corresponding normal tissues from korean patients with breast cancer[J].Ann Lab Med, 2013, 33(6):431-40. doi: 10.3343/alm.2013.33.6.431 [6] Osman A.MicroRNAs in health and disease--basic science and clinical applications[J].Clin Lab, 2012, 58(5/6):393-402. https://www.ncbi.nlm.nih.gov/pubmed/22783567 [7] Pasquinelli AE.MicroRNAs and their targets:recognition, regulation and an emerging reciprocal relationship[J].Nat Rev Genet, 2012, 13(4):271-82. https://www.ncbi.nlm.nih.gov/pubmed/22411466 [8] Lagos-Quintana M, Rauhut R, Yalcin A, et al.Identification of tissue-specific microRNAs from mouse[J].Curr Biol, 2002, 12(9): 735-9. doi: 10.1016/S0960-9822(02)00809-6 [9] Catto JW, Alcaraz A, Bjartell AS, et al.MicroRNA in prostate, bladder, and kidney cancer:a systematic review[J].Eur Urol, 2011, 59(5):671-81. doi: 10.1016/j.eururo.2011.01.044 [10] Iorio MV.Croce CMmicroRNA involvement in human cancer[J]. Carcinogenesis, 2012, 33(6):1126-33. doi: 10.1093/carcin/bgs140 [11] Kong YW, Ferland-Mccollough D, Jackson TJ.microRNAs in cancer management[J].Lancet Oncol, 2012, 13(6):E249-58. doi: 10.1016/S1470-2045(12)70073-6 [12] Lu J, Getz G, Miska EA, et al.MicroRNA expression profiles classify human cancers[J].Nature, 2005, 435(743):834-8. https://www.ncbi.nlm.nih.gov/pubmed/15944708 [13] Ferdin J, Kunej T, Calin G.Non-coding RNAs:identification of cancer-associated microRNAs by gene profiling[J].Technol Cancer Res Treat, 2010, 9(2):123-38. doi: 10.1177/153303461000900202 [14] Sproul D, Meehan RR.Genomic insights into cancer-associated aberrant CpG island hypermethylation[J].Brief Funct Genomics, 2013, 12(3):174-90. doi: 10.1093/bfgp/els063 [15] Liu WR, Shi YH, Peng YF, et al.Epigenetics of hepatocellular carcinoma:a new horizon[J].Chin Med J (Engl), 2012, 125(13): 2349-60. https://www.ncbi.nlm.nih.gov/pubmed/22882861 [16] You JS, Jones PA.Cancer genetics and epigenetics:two sides of the same coin[J].Cancer Cell, 2012, 22(1):9-20. doi: 10.1016/j.ccr.2012.06.008 [17] Saito Y, Liang G, Egger G, et al.Specific activationof microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells[J].Cancer Cell, 2006, 9(6):435-43. doi: 10.1016/j.ccr.2006.04.020 [18] Biagioni F, Bossel Ben-Moshe N, Fontemaggi G, et al.miR-10b*, a master inhibitor of the cell cycle, is down-regulated in human breast tumours[J].EMBO Mol Med, 2012, 4(11):1214-29. doi: 10.1002/emmm.201201483 [19] Morita S, Takahashi RU, Yamashita R, et al.Genome-Wide analysis of DNA methylation and expression of MicroRNAs in breast cancer cells[J].Int J Mol Sci, 2012, 13(7):8259-72. https://www.ncbi.nlm.nih.gov/pubmed/22942701 [20] Zhang Y, Yang P, Sun T, et al.miR-126 and miR-126*repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis[J].Nat Cell Biol, 2013, 15(3):284-94. doi: 10.1038/ncb2690 [21] Baer C, Claus R, Plass C.Genome-Wide epigenetic regulation of miRNAs in cancer[J].Cancer Res, 2013, 73(2):473-7. doi: 10.1158/0008-5472.CAN-12-3731 [22] Ng EK, Li R, Shin VY, et al.MicroRNA-143 is downregulated in breast cancer and regulates DNA methyltransferases 3A in breast cancer cells[Z], 2013. https://www.ncbi.nlm.nih.gov/pubmed/24218337 [23] Sandhu R, Rivenbark AG, Coleman WB.Loss of posttranscriptional regulation of DNMT3b by microRNAs:a possible molecular mechanism for the hypermethylation defect observed in a subset of breast cancer cell lines[J].Int J Oncol, 2012, 41(2):721-32. https://www.ncbi.nlm.nih.gov/pubmed/22664488/ [24] Matsubara N.Epigenetic regulation and colorectal cancer[J].Dis Colon Rectum, 2012, 55(1):96-104. doi: 10.1097/DCR.0b013e318233a1ef [25] Gonzalez CA, Agudo A.Carcinogenesis, prevention and early detection of gastric cancer:Where we are and where we should go[J].Int J Cancer, 2012, 130(4):745-53. doi: 10.1002/ijc.v130.4 [26] Ma XT, Wang YW, Zhang MQ, et al.DNA methylation data analysis and its application to cancer research[J].Epigenomics, 2013, 5(3):301-16. doi: 10.2217/epi.13.26
点击查看大图
计量
- 文章访问数: 506
- HTML全文浏览量: 214
- PDF下载量: 2
- 被引次数: 0